Fluorescent Biosensors for measuring the signaling kinetics of GPCR ligands that activate G12/13 pathways.

G-protein coupled receptors are outstanding drug targets. When the receptor is activated, it signals through heterotrimeric G proteins, which in turn activate various downstream effector proteins. The process of discovering new drugs that activate particular G-protein coupled receptors depends on having functional assays that provide insights into which compounds activate the receptor, which block it, and how long the receptor is active. Today there are good assays for the receptors that activate the Gs, Gi, and Gq proteins. There are remarkably few for the G12/13 family, which is particularly important because this pathway is involved in cancer. The receptors that signal through the G12/13 proteins are involved in cell adhesion, cell invasion, or cell motility, the hallmarks of cancer behavior. Indeed the constitutively active G12 protein can act as an oncogene. Given the biological importance of the receptors that signal through the G12/13 pathway, reliable assays for the activation of this pathway are needed. The first aim of this work is to determine the feasibility of creating a live cell, fluorescent assay for G12/13 pathway activation that 1) can be used on standard plate readers, 2) provides kinetic data about when the pathway is activated, and for how long, 3) involves no additional enzyme substrates that can be depleted, and 4) can be used on a variety of cell types ranging from standard fibroblasts to cancer cell lines. Cross talk often occurs between different G-protein signaling pathways. Some receptors activate multiple different G proteins, and it is often the case that a receptor will activate both the Gq and G12/13 pathways. The second goal of this project is to determine the feasibility of creating CRISPR/Cas9 tools with the specific guide RNAs to selectively knock out different G proteins. These tools would be capable of removing the function of a G protein in a matter of days such that receptor driven signaling could be compared in parallel wells of identical cells missing different signaling pathways. The final goal of the project is to combine the RhoA sensor, CRISPR tools, and biosensors for DAG, Ca2+, cAMP, β-arrestin to completely characterize the PAR1 receptor and potential agonist bias at this receptor in breast cancer cell lines. Project Number: 1R43CA295295-01A1 | Fiscal Year: 2025 | NIH Institute/Center: National Cancer Institute (NCI) | Principal Investigator: THOMAS HUGHES (+1 co-PI) | Institution: MONTANA MOLECULAR, LLC, BOZEMAN, MT | Award Amount: $364,367 | Activity Code: R43 | Study Section: Special Emphasis Panel[ZRG1 MCST-G (15)] View on NIH RePORTER: https://reporter.nih.gov/project-details/11183134